Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 361 to 375 of 482 results for anxiety

  1. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies (TA772)

    Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people aged 3 and older who have had a stem cell transplant or at least 2 previous therapies.

  2. Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)

    Evidence-based recommendations on tildrakizumab (Ilumetri) for treating moderate to severe plaque psoriasis in adults.

  3. Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)

    Evidence-based recommendations on andexanet alfa (Ondexxya) for reversing anticoagulation form apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding.

  4. Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies (TA786)

    Evidence-based recommendations on tucatinib (TUKYSA) for HER2-positive locally advanced or metastatic breast cancer in adults after 2 or more anti-HER2 treatment therapies.

  5. Path Finder for freezing of gait in people with Parkinson's disease (MIB170)

    NICE has developed a medtech innovation briefing (MIB) on Path Finder for freezing of gait in people with Parkinson’s disease .

  6. Virtual ward platform technologies for acute respiratory infections: early value assessment (HTG697)

    Early value assessment (EVA) guidance on virtual ward platform technologies for acute respiratory infections.

  7. Digital self-help for eating disorders: early value assessment (HTG768)

    Early value assessment (EVA) guidance on digital self-help for eating disorders.

  8. Self-harm: assessment, management and preventing recurrence (NG225)

    This guideline covers assessment, management and preventing recurrence for children, young people and adults who have self-harmed. It includes those with a mental health problem, neurodevelopmental disorder or learning disability and applies to all sectors that work with people who have self-harmed.

  9. Acoustic CR Neuromodulation for adults with chronic subjective tonal tinnitus (MIB5)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Acoustic CR Neuromodulation system

  10. Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over (TA1050)

    Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over.

  11. Dupilumab for treating severe asthma with type 2 inflammation (TA751)

    Evidence-based recommendations on dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over.

  12. Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)

    Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (also known as Viekirax) with or without dasabuvir (also known as Exviera) for adults with some types (called genotypes) of chronic hepatitis C.

  13. Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316)

    Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic hormone-relapsed prostate cancer in adults who have had treatment with docetaxel-containing chemotherapy.

  14. Contrast-enhanced spectral mammography for breast cancer (MIB304)

    NICE has developed a medtech innovation briefing (MIB) on contrast-enhanced spectral mammography for breast cancer .

  15. Falls: assessment and prevention in older people and in people 50 and over at higher risk (NG249)

    This guideline covers assessing risk of falling and interventions to prevent falls in all people aged 65 and over, and people aged 50 to 64 who are at higher risk of falls. It aims to reduce the risk and incidence of falls, and the associated distress, pain, injury, loss of confidence, loss of independence and mortality.